FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options.
Revolutions Medicines’ daraxonrasib met the main goals of its Phase 3 test in pancreatic cancer, posting results that were both statistically significant and clinically meaningful. The company now plans to file for speedy regulatory approval under a new FDA pilot program.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.